Sir
In your excellent News story “Epidemiology gains an ally in bioweapons surveillance project” (Nature 411, 228; 2001), summarizing the rapid syndrome validation project (RSVP) for early 'syndrome-based' epidemiological reporting, you faithfully reported my statement that “This rapid reporting already appears to have this year averted two outbreaks of hepatitis A” and that antiviral-drug prescription frequency may have been altered.
This information was incorrect. I based these statements on early, anecdotal evidence that I cannot fully support. I should have checked my sources more carefully. I regret the error, and take full responsibility for it. All other aspects of the News story are accurate.
I look forward to reporting, in a future paper, the benefits and downsides of the novel systematic approach to disease reporting that we are taking at RSVP, once we have accumulated a sufficiently large database. We are fortunate to have funding from the US Department of Energy to expand the project to multiple reporting sites in various clinical settings, including non-academic medical clinics and public-health clinics on both sides of the Mexico–US border.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zelicoff, A. Enthusiasm ran ahead of discoveries still to come. Nature 413, 108 (2001). https://doi.org/10.1038/35093275
Issue Date:
DOI: https://doi.org/10.1038/35093275